サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：憩室炎疾患の市場シェア、規模、動向、産業分析レポート、タイプ別、治療法別、エンドユーザー別、地域別、セグメント別予測、2023-2032年
市場調査レポート
商品コード
1287681

憩室炎疾患の市場シェア、規模、動向、産業分析レポート、タイプ別、治療法別、エンドユーザー別、地域別、セグメント別予測、2023-2032年

Diverticulitis Disease Market Share, Size, Trends, Industry Analysis Report, By Type (Uncomplicated, Complicated); By Treatment; By End-User; By Region; Segment Forecast, 2023-2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
憩室炎疾患の市場シェア、規模、動向、産業分析レポート、タイプ別、治療法別、エンドユーザー別、地域別、セグメント別予測、2023-2032年
出版日: 2023年04月01日
発行: Polaris Market Research
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris market researchの新しい調査によると、世界の憩室炎疾患市場規模は2032年までに38億6,000万米ドルに達すると予想されています。本レポートでは、現在の市場力学を詳細に把握し、将来の市場成長に関する分析を提供しています。

高齢者人口の増加は、患者数の増加を引き起こし、憩室性疾患の市場を拡大させます。そのため、世界市場では、治療法改善のための薬剤の需要が予測されています。また、最先端医療への需要の高まり、タバコの喫煙率の上昇、若者の座りがちなライフスタイルへの移行などが主な要因となっています。例えば、CDCの2022年の報告書によると、ウェストバージニア州の喫煙率は23.8％と米国で最も高い数値となっています。予防可能な病気の主要な原因＆米国だけで実質的な死亡を記録した喫煙は、毎年ほぼ50万48万人の死亡を占めています。しかし、CDCの予測によると、2020年には3,080万人のアメリカ人、つまり成人の12.5％がタバコを吸っているといいます。

大腸の憩室症や憩室性疾患は、世界的に一般的になってきています。大多数の患者は非常に長い間無症状のままであるにもかかわらず、大腸の憩室性疾患、特に急性憩室炎はかなり多く、国の医療制度に大きな財政負担をかけ始めています。例えば、2022年に発表されたAlexander T. Hawkinsの研究論文によると、S状結腸の憩室症は60歳以上の約33％に発症し、先進国では頻度が高いとされています。憩室炎は、これらの患者の最大15%に、人生のある時期に発生する可能性があります。

現在、数多くの治療法を検証し、最良の治療戦略を決定することが重視されています。しかし、残念ながら、急性憩室炎の再発を予防するための薬物療法の有効性を裏付ける確かなデータはまだ不足しています。ここでは、これらの治療法の有効性と今後の展望を簡潔に説明します。

憩室疾患市場レポートハイライト

  • 2022年は「合併症なし」が主要な売上を占め、市場を独占します。市場拡大の主な理由は、抗生物質治療研究の継続的な進歩です。
  • 2022年、薬物療法が市場を独占します。市場の成長を促す主な要素は、急性憩室炎で生じる可能性のある感染症を治療するための抗生物質の使用であるため、このカテゴリーはその恩恵を受けています。
  • 2022年、病院が市場の最大の収益部分を占める。市場成長の主要な促進要因は、適切な検査を選択するために患者を指導できる専門家が病院に存在することです。
  • 2022年には、北米が世界の収入の大半を占める。予測期間中、高齢者人口の増加や地域の健康問題に対する人々の意識の拡大などの要素から、この市場は利益を得ると予測されています。
  • 世界的に事業を展開する企業には、Sucampo Pharmaceuticals、Valeant Pharmaceuticals International、Synergy Pharmaceuticals、Ardelyx、Astellas Pharma、Novartis AG、Hikma Pharmaceuticals、Baxter Internationalがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の憩室炎疾患市場に関する洞察

  • 憩室炎疾患市場- エンドユーザーのスナップショット
  • 憩室炎疾患市場力学
    • 促進要因と機会
      • 座りっぱなしのライフスタイルへの適応の増加と胃腸の大幅な成長
      • 経口薬の需要の高まり
    • 抑制要因と課題
      • 高コスト
  • PESTEL分析
  • 憩室炎疾患市場のエンドユーザー動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の憩室炎疾患市場、種類別

  • 主な調査結果
  • イントロダクション
  • 複雑でない
  • 煩雑

第6章 世界の憩室炎疾患市場、治療別

  • 主な調査結果
  • イントロダクション
  • 薬
  • 手術
  • 支持療法
  • ペニシリン系抗生物質
  • 抗生物質
  • 栄養補助食品
  • 点滴輸液

第7章 世界の憩室炎疾患市場、エンドユーザー別

  • 主な調査結果
  • イントロダクション
  • 専門センター
  • 病院
  • 研究センター

第8章 世界の憩室炎疾患市場、地域別

  • 主な調査結果
  • イントロダクション
    • 憩室炎疾患市場評価、地域別、2019-2032年
  • 憩室炎疾患市場-北米
    • 北米：憩室炎疾患市場、種類別、2019-2032年
    • 北米：憩室炎疾患市場、エンドユーザー別、2019～2032年
    • 北米：憩室炎疾患市場、治療別、2019-2032年
    • 憩室炎疾患市場-米国
    • 憩室炎疾患市場- カナダ
  • 憩室炎疾患市場- 欧州
    • 欧州：憩室炎疾患市場、種類別、2019～2032年
    • 欧州：憩室炎疾患市場、エンドユーザー別、2019～2032年
    • 欧州：憩室炎疾患市場、治療別、2019～2032年
    • 憩室炎疾患市場- 英国
    • 憩室炎疾患市場- フランス
    • 憩室炎疾患市場- ドイツ
    • 憩室炎疾患市場- イタリア
    • 憩室炎疾患市場- スペイン
    • 憩室炎疾患市場- オランダ
    • 憩室炎疾患市場- ロシア
  • 憩室炎疾患市場- アジア太平洋
    • アジア太平洋：憩室炎疾患市場、種類別、2019～2032年
    • アジア太平洋：憩室炎疾患市場、エンドユーザー別、2019～2032年
    • アジア太平洋：憩室炎疾患市場、治療別、2019～2032年
    • 憩室炎疾患市場- 中国
    • 憩室炎疾患市場- インド
    • 憩室炎疾患市場- マレーシア
    • 憩室炎疾患市場- 日本
    • 憩室炎疾患市場- インドネシア
    • 憩室炎疾患市場- 韓国
  • 憩室炎疾患市場-中東およびアフリカ
    • 中東およびアフリカ：憩室炎疾患市場、種類別、2019～2032年
    • 中東およびアフリカ：憩室炎疾患市場、エンドユーザー別、2019～2032年
    • 中東およびアフリカ：憩室炎疾患市場、治療別、2019～2032年
    • 憩室炎疾患市場- サウジアラビア
    • 憩室炎疾患市場- UAE
    • 憩室炎疾患市場- イスラエル
    • 憩室炎疾患市場- 南アフリカ
  • 憩室炎疾患市場-ラテンアメリカ
    • ラテンアメリカ：憩室炎疾患市場、種類別、2019-2032年
    • ラテンアメリカ：憩室炎疾患市場、エンドユーザー別、2019～2032年
    • ラテンアメリカ：憩室炎疾患市場、治療別、2019～2032年
    • 憩室炎疾患市場- メキシコ
    • 憩室炎疾患市場- ブラジル
    • 憩室炎疾患市場- アルゼンチン

第9章 競合情勢

  • 拡張と買収の分析
    • 拡張
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • Pfizer
  • G.D. Searle
  • Teva Pharmaceutical
  • Abbott Laboratories
  • Braun Medical
  • GSK
  • Bayer HealthCare
  • Roche Holding
  • Johnson and Johnson
  • Sucampo Pharmaceuticals
  • Valeant Pharmaceuticals
  • Synergy Pharmaceuticals
  • Ardelyx
  • Astellas Pharma
  • Novartis
  • Hikma Pharmaceuticals
  • Baxter International
図表

List of Tables

  • Table 1 Global Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 3 Global Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 4 Diverticulitis Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 7 North America: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 8 U.S.: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 10 U.S.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 11 Canada: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 13 Canada: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 14 Europe: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 16 Europe: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 17 UK: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 19 UK: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 20 France: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 22 France: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 23 Germany: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 25 Germany: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 26 Italy: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 28 Italy: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 29 Spain: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 31 Spain: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 35 Russia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 37 Russia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 41 China: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 43 China: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 44 India: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 46 India: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 50 Japan: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 52 Japan: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 56 South Korea: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 58 South Korea: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 65 UAE: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 67 UAE: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 68 Israel: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 70 Israel: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 71 South Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 73 South Africa: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 74 Latin America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 76 Latin America: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 77 Mexico: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 79 Mexico: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 80 Brazil: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 82 Brazil: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 83 Argentina: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 85 Argentina: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Diverticulitis Disease Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Diverticulitis Disease Market, by Treatment, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Diverticulitis Disease Market, by Type, 2021 & 2030 (USD Billion)
  • Figure 10. Market by End-User
  • Figure 11. Global Diverticulitis Disease Market, by End-User, 2021 & 2030 (USD Billion)
  • Figure 12. Diverticulitis Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Diverticulitis Disease Market
目次
Product Code: PM3168

The global diverticulitis disease market size is expected to reach USD 3.86 billion by 2032, according to a new study by Polaris market research. The report "Diverticular Disease Market Share, Size, Trends, Industry Analysis Report, By Type (Uncomplicated, Complicated); By Treatment; By End-User; By Region; Segment Forecast, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rise in the elderly population causes a rise in the patient population, which in turn increases the market for diverticular illness. The worldwide market has therefore forecast the demand for medications for improved treatment. It has been primarily fueled by the rising demand for cutting-edge medical care, the rise in cigarette smoking, and the broad movement of young people toward sedentary lifestyles. For instance, West Virginia had the highest smoking rate in the United States in 2022, with a rate of 23.8%, according to the CDC's 2022 report. The leading cause of the preventable disease & recorded substantial deaths in the U.S alone, smoking accounts for almost 500,000 480,000 deaths annually. However, the CDC predicted that 30.8 million Americans or 12.5% of adults smoked cigarettes in 2020.

Diverticulosis and diverticular disease of the colon are becoming more common worldwide. Despite the fact that the majority of patients stay asymptomatic for a very long time, diverticular illness of the colon, particularly acute diverticulitis, is quite common and is beginning to put a large financial strain on national health systems. For instance, a research paper by Alexander T. Hawkins, published in 2022, states that diverticulosis of the sigmoid colon affects about 33% of people over the age of 60 and is frequent in the industrialized world. Diverticulitis could occur in up to 15% of these patients at some time in their lives.

The current emphasis is on determining the best therapy strategy through the testing of numerous treatments. Unfortunately, there is still a lack of solid data supporting the efficacy of a medicinal approach to preventing a recurrence of acute diverticulitis. Here, we give a succinct overview of these treatments' efficacy and prospects for the future.

Diverticular Disease Market Report Highlights

  • Uncomplicated will dominate the market in 2022, accounting for major sales. The primary reason for the market's expansion is the ongoing advancement in antibiotic treatment research.
  • In 2022, medications will rule the market. Since the primary element driving market growth is the use of antibiotics to treat infections that may arise in acute diverticulitis, the category benefits from this.
  • In 2022, hospitals made up the greatest revenue portion of the market. The key driver of market growth is the presence of experts in hospitals who can guide patients in selecting appropriate tests.
  • North America will produce majority of global income in 2022. Over the course of the forecast period, the market is predicted to gain from elements including the growing senior population and expanding public awareness of local health issues.
  • The global players with global presence include Sucampo Pharmaceuticals, Valeant Pharmaceuticals International, Synergy Pharmaceuticals, Ardelyx, Astellas Pharma, Novartis AG, Hikma Pharmaceuticals and Baxter International.

Polaris Market Research has segmented the Diverticular Disease Market report based on type, treatment, end-user and region:

Diverticular Disease, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Uncomplicated
  • Complicated

Diverticular Disease, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

  • Medications
  • Surgery
  • Supportive care
  • Penicillin Antibiotic
  • Antibiotics
  • Dietary Supplements
  • IV fluids

Diverticular Disease, End-User Outlook (Revenue - USD Billion, 2019 - 2032)

  • Specialty centers
  • Hospitals
  • Research centers

Diverticular Disease, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Diverticulitis Disease Market Insights

  • 4.1. Diverticulitis Disease Market - End-User Snapshot
  • 4.2. Diverticulitis Disease Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased sedentary lifestyle adaptation and significant gastrointestinal growth
      • 4.2.1.2. Rising Demand for Oral Drugs
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Diverticulitis Disease Market End-User Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Diverticulitis Disease Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Uncomplicated
    • 5.3.1. Global Diverticulitis Disease Market, by Uncomplicated, by Region, 2019-2032 (USD Billion)
  • 5.4. Complicated
    • 5.4.1. Global Diverticulitis Disease Market, by Complicated, by Region, 2019-2032 (USD Billion)

6. Global Diverticulitis Disease Market, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 6.3. Medications
    • 6.3.1. Global Diverticulitis Disease Market, by Medications, by Region, 2019-2032 (USD Billion)
  • 6.4. Surgery
    • 6.4.1. Global Diverticulitis Disease Market, by Surgery, by Region, 2019-2032 (USD Billion)
  • 6.5. Supportive care
    • 6.5.1. Global Diverticulitis Disease Market, by Supportive care, by Region, 2019-2032 (USD Billion)
  • 6.6. Penicillin Antibiotic
    • 6.6.1. Global Diverticulitis Disease Market, by Penicillin Antibiotic, by Region, 2019-2032 (USD Billion)
  • 6.7. Antibiotics
    • 6.7.1. Global Diverticulitis Disease Market, by Antibiotics, by Region, 2019-2032 (USD Billion)
  • 6.8. Dietary Supplements
    • 6.8.1. Global Diverticulitis Disease Market, by Dietary Supplements, by Region, 2019-2032 (USD Billion)
  • 6.9. IV fluids
    • 6.9.1. Global Diverticulitis Disease Market, by IV fluids, by Region, 2019-2032 (USD Billion)

7. Global Diverticulitis Disease Market, by End-User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • 7.3. Specialty centres
    • 7.3.1. Global Diverticulitis Disease Market, by Specialty centres, By Region, 2019-2032 (USD Billion)
  • 7.4. Hospitals
    • 7.4.1. Global Diverticulitis Disease Market, by Hospitals, By Region, 2019-2032 (USD Billion)
  • 7.5. Research centres
    • 7.5.1. Global Diverticulitis Disease Market, by Research centres, By Region, 2019-2032 (USD Billion)

8. Global Diverticulitis Disease Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Diverticulitis Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Diverticulitis Disease Market - North America
    • 8.3.1. North America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.3.3. North America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.4. Diverticulitis Disease Market - U.S.
      • 8.3.4.1. U.S.: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.5. Diverticulitis Disease Market - Canada
      • 8.3.5.1. Canada: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.4. Diverticulitis Disease Market - Europe
    • 8.4.1. Europe: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.4. Diverticulitis Disease Market - UK
      • 8.4.4.1. UK: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.5. Diverticulitis Disease Market - France
      • 8.4.5.1. France: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.6. Diverticulitis Disease Market - Germany
      • 8.4.6.1. Germany: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.7. Diverticulitis Disease Market - Italy
      • 8.4.7.1. Italy: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.8. Diverticulitis Disease Market - Spain
      • 8.4.8.1. Spain: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.9. Diverticulitis Disease Market - Netherlands
      • 8.4.9.1. Netherlands: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.10. Diverticulitis Disease Market - Russia
      • 8.4.10.1. Russia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.5. Diverticulitis Disease Market - Asia Pacific
    • 8.5.1. Asia Pacific: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.4. Diverticulitis Disease Market - China
      • 8.5.4.1. China: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.5. Diverticulitis Disease Market - India
      • 8.5.5.1. India: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.6. Diverticulitis Disease Market - Malaysia
      • 8.5.6.1. Malaysia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.7. Diverticulitis Disease Market - Japan
      • 8.5.7.1. Japan: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.8. Diverticulitis Disease Market - Indonesia
      • 8.5.8.1. Indonesia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.9. Diverticulitis Disease Market - South Korea
      • 8.5.9.1. South Korea: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.6. Diverticulitis Disease Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.4. Diverticulitis Disease Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.5. Diverticulitis Disease Market - UAE
      • 8.6.5.1. UAE: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.6. Diverticulitis Disease Market - Israel
      • 8.6.6.1. Israel: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.7. Diverticulitis Disease Market - South Africa
      • 8.6.7.1. South Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.7. Diverticulitis Disease Market - Latin America
    • 8.7.1. Latin America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.4. Diverticulitis Disease Market - Mexico
      • 8.7.4.1. Mexico: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.5. Diverticulitis Disease Market - Brazil
      • 8.7.5.1. Brazil: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.6. Diverticulitis Disease Market - Argentina
      • 8.7.6.1. Argentina: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Pfizer
    • 10.1.1. Company Overview
    • 10.1.2. Financial PerTreatmentance
    • 10.1.3. Treatment Benchmarking
    • 10.1.4. Recent Development
  • 10.2. G.D. Searle
    • 10.2.1. Company Overview
    • 10.2.2. Financial PerTreatmentance
    • 10.2.3. Treatment Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Teva Pharmaceutical
    • 10.3.1. Company Overview
    • 10.3.2. Financial PerTreatmentance
    • 10.3.3. Treatment Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Abbott Laboratories
    • 10.4.1. Company Overview
    • 10.4.2. Financial PerTreatmentance
    • 10.4.3. Treatment Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Braun Medical
    • 10.5.1. Company Overview
    • 10.5.2. Financial PerTreatmentance
    • 10.5.3. Treatment Benchmarking
    • 10.5.4. Recent Development
  • 10.6. GSK
    • 10.6.1. Company Overview
    • 10.6.2. Financial PerTreatmentance
    • 10.6.3. Treatment Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Bayer HealthCare
    • 10.7.1. Company Overview
    • 10.7.2. Financial PerTreatmentance
    • 10.7.3. Treatment Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Roche Holding
    • 10.8.1. Company Overview
    • 10.8.2. Financial PerTreatmentance
    • 10.8.3. Treatment Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Johnson and Johnson
    • 10.9.1. Company Overview
    • 10.9.2. Financial PerTreatmentance
    • 10.9.3. Treatment Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sucampo Pharmaceuticals
    • 10.10.1. Company Overview
    • 10.10.2. Financial PerTreatmentance
    • 10.10.3. Treatment Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Valeant Pharmaceuticals
    • 10.11.1. Company Overview
    • 10.11.2. Financial PerTreatmentance
    • 10.11.3. Treatment Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Synergy Pharmaceuticals
    • 10.12.1. Company Overview
    • 10.12.2. Financial PerTreatmentance
    • 10.12.3. Treatment Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Ardelyx
    • 10.13.1. Company Overview
    • 10.13.2. Financial PerTreatmentance
    • 10.13.3. Treatment Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Astellas Pharma
    • 10.14.1. Company Overview
    • 10.14.2. Financial PerTreatmentance
    • 10.14.3. Treatment Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Novartis
    • 10.15.1. Company Overview
    • 10.15.2. Financial PerTreatmentance
    • 10.15.3. Treatment Benchmarking
    • 10.15.4. Recent Development
  • 10.16. Hikma Pharmaceuticals
    • 10.16.1. Company Overview
    • 10.16.2. Financial PerTreatmentance
    • 10.16.3. Treatment Benchmarking
    • 10.16.4. Recent Development
  • 10.17. Baxter International
    • 10.17.1. Company Overview
    • 10.17.2. Financial PerTreatmentance
    • 10.17.3. Treatment Benchmarking
    • 10.17.4. Recent Development